Private Trust Company’s NovoCure NVCR Stock Holding History

Private Trust Company’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-31	Closed	-$1.29K	–	2364
2023 Q2	$1.29K	Hold	31	–	–	﹤0.01%	2161
2023 Q1	$1.86K	Sell	31 -10	-24%	-$799	﹤0.01%	2095
2022 Q4	$3K	Sell	41 -13	-24%	-$978	﹤0.01%	1945
2022 Q3	$4K	Hold	54	–	–	﹤0.01%	1747
2022 Q2	$4K	Buy	+54	New	+$4.07K	﹤0.01%	1817

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Private Trust Company's NVCR Position: Q3 2023 in Review

Private Trust Company sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 31 shares — an estimated $1.29K sold.

Private Trust Company first reported a position in NVCR in Q2 2022 and held it in 5 quarters. The position peaked at $4K in Q3 2022. 226 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

Private Trust Company reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
Private Trust Company sold 31 NovoCure shares in Q3 2023, an estimated $1.29K.
Private Trust Company first reported a position in NovoCure in Q2 2022 and held it in 5 quarters.
Private Trust Company's NovoCure position peaked at $4K in Q3 2022.
226 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on Private Trust Company's 13F filing for Q3 2023, filed 18 Oct 2023.